Multiple endocrine neoplasia type 2 secondary prevention

Multiple endocrine neoplasia type 2 Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multiple endocrine neoplasia type 2 from other Diseases
Epidemiology & Demographics
Risk Factors
Screening
Natural History, Complications & Prognosis
Diagnosis
Diagnostic Criteria
History & Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Multiple endocrine neoplasia type 2 secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multiple endocrine neoplasia type 2 secondary prevention
CDC on Multiple endocrine neoplasia type 2 secondary prevention
Multiple endocrine neoplasia type 2 secondary prevention in the news
Blogs on Multiple endocrine neoplasia type 2 secondary prevention
Directions to Hospitals Treating Multiple endocrine neoplasia type 2
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, surveillance for multiple endocrine neoplasia type 2 by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catecholamines is recommended post-surgically to monitor for recurrence and complications for multiple endocrine neoplasia type 2.

Secondary Prevention

According to the American Society of Clinical Oncology, surveillance for multiple endocrine neoplasia type 2 is recommended post-surgically to monitor for recurrence and complications, by annual measurement of:

• Serum calcitonin
• Serum calcium
• Serum parathyroid hormone
• Catecholamines

References

​​​

Template:WikiDoc Sources